Cubist gets fast-track status in 2 areas for antibiotic combo

05/8/2013 | American City Business Journals

The FDA granted fast-track status to Cubist Pharmaceuticals' late-stage antibiotic CXA-201, a combination of ceftolozane and tazobactam, as a treatment for hospital-acquired bacterial pneumonia and complicated urinary tract infections. The antibiotic, which already received a fast-track designation for complicated intra-abdominal infections, is in two Phase III trials for the urinary and abdominal indications. Cubist plans to initiate another late-stage trial against ventilator-associated pneumonia in the coming months.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ